Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-09-03 DOI:10.1080/14796694.2024.2391270

Suresh S Ramalingam, Jennifer W Carlisle

引用次数: 0

Abstract

Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer.

查看原文本刊更多论文

安可非尼加比尼替尼治疗 BRAF V600E 突变转移性 NSCLC：PHAROS 2 期研究的临床意义。

Ramalingam 博士和 Carlisle 博士讨论了 BRAF V600E 突变转移性非小细胞肺癌的发病率和病理生理学以及当前的治疗方案。播客概述了最近由辉瑞赞助的 PHAROS (NCT03915951) 2 期研究的数据，这些数据是美国食品药品管理局最近批准安戈非尼加比尼替尼治疗 BRAF V600E 突变转移性非小细胞肺癌的依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.

文献相关原料

公司名称	产品信息	采购帮参考价格